Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2012 update. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf [last accessed 19 Nov 2013]
   Google Scholar
• Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007;132:1882–1889
   PubMed Web of Science ®Google Scholar
• Guerra S, Martinez FD. Epidemiology of the origins of airflow limitation in asthma. Proc Am Thorac Soc 2009;6:707–711
   PubMedGoogle Scholar
• Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011;364:2006–2015
   PubMed Web of Science ®Google Scholar
• Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, Chung KF, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012;185:356–362
   PubMed Web of Science ®Google Scholar
• Bergeron C, Al-Ramil W, Hamid Q. Remodeling in asthma. Proc Am Thorac Soc 2009;6:301–305
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2013 update. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf [last accessed 19 Nov 2013]
   Google Scholar
• Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63:1046–1051
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179–187
   PubMed Web of Science ®Google Scholar
• Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present, and future. Eur Respir J 2010;36:12–19
   PubMed Web of Science ®Google Scholar
• Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, Antó JM, Künzli N, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008;63:1040–1045
   PubMed Web of Science ®Google Scholar
• Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 2007;29:823–843
   PubMed Web of Science ®Google Scholar
• Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomized clinical trial. Drugs 2006;66:2235–2254
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107–1136
   PubMed Web of Science ®Google Scholar
• Teeter JG, Bleeker EG. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998;113:272–277
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549–565
   PubMed Web of Science ®Google Scholar
• Persdotter S, Lindahl M, Malm-Erjeflt M, von Wachenfeldt K, Korn SH, Stevens T, Miller-Larsson A. Cooperative inhibitory effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium. Int Arch Allergy Immunol 2007;143:201–210
   PubMedGoogle Scholar
• Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 2002;57:237–241
   PubMed Web of Science ®Google Scholar
• Cooper PR, Kurten RC, Zhang J, Nicholls DJ, Dainty IA, Panettieri RA. Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms. Br J Pharmacol 2011;163:521–532
   PubMed Web of Science ®Google Scholar
• Horvath G, Mendes ES, Schmid N, Schmid A, Conner GE, Fregien NL, Salathe M, Wanner A. Rapid nongenomic actions of inhaled corticosteroids on long-acting β2-agonist transport in the airway. Pulmon Pharmacol Ther 2011;24:654–659
   PubMedGoogle Scholar
• Skevaki CL, Christodoulou I, Spyridaki IS, Tiniakou I, Georgiou V, Xepapadaki P, Kafetzis DA, Papadopoulos NG. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy 2009;39:1700–1710
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma – Full Report 2007. NIH Publication Number 08-4051, 2007
   Google Scholar